Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Fireman B.V. (IFRX)

Fireman B.V. (IFRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 74,193
  • Shares Outstanding, K 58,883
  • Annual Sales, $ 70 K
  • Annual Income, $ -46,180 K
  • 60-Month Beta 1.27
  • Price/Sales 1,095.40
  • Price/Cash Flow N/A
  • Price/Book 0.69
Trade IFRX with:

Options Overview Details

View History
  • Implied Volatility 331.08% ( +18.92%)
  • Historical Volatility 65.61%
  • IV Percentile 96%
  • IV Rank 39.53%
  • IV High 832.82% on 01/23/24
  • IV Low 3.10% on 10/11/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 95
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 2,226
  • Open Int (30-Day) 1,484

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.24
  • Number of Estimates 3
  • High Estimate -0.23
  • Low Estimate -0.26
  • Prior Year -0.27
  • Growth Rate Est. (year over year) +11.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2400 +1.61%
on 04/17/24
1.8200 -30.77%
on 03/19/24
-0.2400 (-16.00%)
since 03/18/24
3-Month
1.2400 +1.61%
on 04/17/24
1.9200 -34.38%
on 02/29/24
-0.3400 (-21.25%)
since 01/18/24
52-Week
1.1400 +10.53%
on 11/10/23
5.2000 -75.77%
on 05/15/23
-2.9800 (-70.28%)
since 04/18/23

Most Recent Stories

More News
WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients

/PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced the...

IFRX : 1.2600 (-0.40%)
Biotech Stock Roundup: MRNA Provides Update, KALA, IFRX Surge on Regulatory News

Regulatory and pipeline updates from Moderna (MRNA) and KALA are the key highlights for the biotech sector.

MRNA : 101.70 (-0.29%)
IFRX : 1.2600 (-0.40%)
KALA : 6.81 (-0.41%)
Stock Index Futures Move Higher Ahead of U.S. Inflation Data, Fed Minutes

June S&P 500 futures (ESM23) are up +0.28%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.21% this morning after three major U.S. benchmark indices finished the regular session mixed as market participants...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
CAT : 356.75 (-0.33%)
VOLVB.S.DX : 280.400 (-3.91%)
HTCR : 1.0200 (+7.36%)
HZON : 11.33 (+0.09%)
CFLT : 27.30 (-0.40%)
IFRX : 1.2600 (-0.40%)
MDB : 335.30 (-0.07%)
Why InflaRx Stock Skyrocketed This Week

The biopharmaceutical company's near-term sales outlook has gotten a huge boost following Emergency Use Authorization for one of its drugs.

RJF : 121.96 (+0.02%)
IFRX : 1.2600 (-0.40%)
Why Shares of InflaRx Are Soaring Wednesday

A key EUA from the FDA for the company's COVID-19 therapy gave the stock a jolt.

IFRX : 1.2600 (-0.40%)
InflaRx (IFRX) Stock Up on FDA's EUA for COVID-19 Treatment

InflaRx (IFRX) shares gain as it receives emergency-use authorization from the FDA for Gohibic (vilobelimab) to treat COVID-19 in terminally-ill patients.

CRSP : 56.00 (-0.28%)
IFRX : 1.2600 (-0.40%)
KALA : 6.81 (-0.41%)
KOD : 3.47 (-3.61%)
Stock Index Futures Move Lower as Recession Fears Weigh on Sentiment

June S&P 500 futures (ESM23) are down -0.22%, and June Nasdaq 100 E-Mini futures (NQM23) are down -0.23% this morning after three major U.S. benchmark indices finished the regular session lower as a swathe...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
CAT : 356.75 (-0.33%)
JPM : 181.44 (+0.10%)
SW.FP : 78.700 (+1.81%)
KRUS : 109.04 (-0.87%)
IFRX : 1.2600 (-0.40%)
JNJ : 145.54 (-0.14%)
SGH : 17.41 (-1.75%)
BE : 9.83 (+0.85%)
CI : 348.78 (+0.78%)
InflaRx Reports Second Quarter 2022 Financial & Operating Results

Fast Track and Orphan Drug designation for vilobelimab in pyoderma gangrenosum (PG) granted by the FDAPlans to submit EUA with the FDA for vilobelimab in...

IFRX : 1.2600 (-0.40%)
InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients

Completed encouraging Type B meeting with US FDAApplication for EUA planned to be submitted in Q3 2022 JENA, Germany, July 26, 2022 (GLOBE NEWSWIRE) --...

IFRX : 1.2600 (-0.40%)
InflaRx Receives FDA Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum

US Food and Drug Administration awards Fast Track designation for the treatment of ulcerative pyoderma gangrenosumFast track follows recently reported...

IFRX : 1.2600 (-0.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

InflaRx N.V. is a clinical-stage biopharmaceutical company. It focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. InflaRx N.V. is based in Germany.

See More

Key Turning Points

3rd Resistance Point 1.5400
2nd Resistance Point 1.4800
1st Resistance Point 1.3700
Last Price 1.2600
1st Support Level 1.2000
2nd Support Level 1.1400
3rd Support Level 1.0300

See More

52-Week High 5.2000
Fibonacci 61.8% 3.6491
Fibonacci 50% 3.1700
Fibonacci 38.2% 2.6909
Last Price 1.2600
52-Week Low 1.1400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar